Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 20;12(6):2382.
doi: 10.3390/jcm12062382.

Prognostic Role of Visual Evoked Potentials in Non-Neuritic Eyes at Multiple Sclerosis Diagnosis

Domizia Vecchio  1   2 , Paolo Barbero  1 , Giulia Galli  1 , Eleonora Virgilio  1   3 , Paola Naldi  1 , Cristoforo Comi  1   2 , Roberto Cantello  1   2
Affiliations

Prognostic Role of Visual Evoked Potentials in Non-Neuritic Eyes at Multiple Sclerosis Diagnosis

Domizia Vecchio et al. J Clin Med. .

Abstract

Introduction: This study aimed to assess the prognostic role of visual evoked potentials (VEPs) of the non-neuritic eye at the diagnosis of multiple sclerosis (MS). Patients and methods: We enrolled 181 MS patients (62% females, mean age at diagnosis: 38 years, standard deviation: 12) at the time of the first diagnostic work-up, including VEPs. We collected P100 latency and N75-P100 amplitude of non-neuritic eyes at diagnosis, and then we calculated the mean values in 127 patients with no history of optic neuritis (ON) or considered the unaffected eye in the remaining. At last follow-up (minimum: one year), disability was evaluated according to MS Severity Score or MSSS (median: 2.44, range: 0.18-9.63). Statistical analysis included Mann-Whitney descriptive analysis, Spearman correlation for independent samples, and linear regression for significant predictors of MSSS. Results: 38/181 patients had P100 latency >115 ms, and 63/181 showed N75-P100 amplitude < 5 microV in the unaffected eyes at MS diagnosis. At last follow-up, MSSS correlated with P100 latency (rho = 0.21, p = 0.004) and N75-P100 amplitude (rho = 0.19, p = 0.009) collected at diagnosis. P100 latency (not N75-P100 amplitude) resulted in a predictor for disability over time (MSSS) in the regression model (along with age at onset, MS course, and disease-modifying treatments). Conclusions: Our study showed a prognostic value of VEPs in clinically unaffected eyes at MS diagnosis to predict future disability, independently from a history of ON.

Keywords: P100 latency; disability outcome; multiple sclerosis; non-neuritic eye; prognosis; visual evoked potentials.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Disability at last follow-up according to baseline P100 latency in non-neuritic eyes (p = 0.004).
Figure 2
Figure 2
Disability at last follow-up according to baseline N75-P100 amplitude in non-neuritic eyes (p = 0.009).
See this image and copyright information in PMC

References

    1. Martínez-Lapiscina E.H., Sanchez-Dalmau B.F., Fraga-Pumar E., Ortiz-Perez S., Tercero-Uribe A.I., Torres-Torres R., Villoslada P. The visual pathway as a model to understand brain damage in multiple sclerosis. Mult. Scler. 2014;20:1678–1685. doi: 10.1177/1352458514542862. - DOI - PubMed
    1. Klistorner A., Garrick R., Barnett M.H., Graham S.L., Arvind H., Sriram P., Yiannikas C. Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential. Neurology. 2013;80:242–245. doi: 10.1212/WNL.0b013e31827deb39. - DOI - PubMed
    1. Janáky M., Jánossy, Horváth G., Benedek G., Braunitzer G. VEP and PERG in patients with multiple sclerosis, with and without a history of optic neuritis. Doc. Ophthalmol. 2017;134:185–193. doi: 10.1007/s10633-017-9589-7. - DOI - PubMed
    1. Odom J.V., International Society for Clinical Electrophysiology of Vision. Bach M., Brigell M., Holder G.E., McCulloch D.L., Mizota A., Tormene A.P. International Society for Clinical Electrophysiology of Vision. ISCEV standard for clinical visual evoked potentials: (2016 update) Doc. Ophthalmol. 2016;133:1–9. doi: 10.1007/s10633-016-9553-y. - DOI - PubMed
    1. Bsteh G., Ehling R., Lutterotti A., Hegen H., Di Pauli F., Auer M., Deisenhammer F., Reindl M., Berger T. Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. PLoS ONE. 2016;11:e0158978. doi: 10.1371/journal.pone.0158978. - DOI - PMC - PubMed

LinkOut - more resources